Oncology Institute (NASDAQ:TOI) vs. Todos Med (OTCMKTS:TOMDF) Financial Contrast

Todos Med (OTCMKTS:TOMDF) and Oncology Institute (NASDAQ:TOI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Todos Med and Oncology Institute, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Todos Med	0	0	0	0	0.00
Oncology Institute	1	0	4	0	2.60

Oncology Institute has a consensus price target of $7.75, indicating a potential upside of 38.39%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than Todos Med.

Risk and Volatility

Todos Med has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Insider and Institutional Ownership

36.9% of Oncology Institute shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Todos Med and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Todos Med	N/A	N/A	N/A
Oncology Institute	-7.42%	N/A	-24.68%

Earnings & Valuation

This table compares Todos Med and Oncology Institute”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Todos Med	N/A	N/A	N/A	N/A	N/A
Oncology Institute	$502.73 million	1.10	-$60.61 million	($0.37)	-15.14

Todos Med has higher earnings, but lower revenue than Oncology Institute.

Summary

Oncology Institute beats Todos Med on 7 of the 9 factors compared between the two stocks.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.